Natural and synthetic antifibrinolytics: inert, poisonous or therapeutic agents?
Hardy
J F
JF
Bélisle
S
S
D015119:Aminocaproic Acid / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007611:Aprotinin / Q000627:therapeutic use; D001803:Blood Transfusion; D002315:Cardiopulmonary Bypass; D004334:Drug Administration Schedule; D005112:Extracorporeal Circulation; D006488:Hemostasis, Surgical; D006490:Hemostatics / Q000627:therapeutic use; D006801:Humans; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D012107:Research Design; D012307:Risk Factors; D015842:Serine Proteinase Inhibitors / Q000097:blood; D013903:Thoracic Surgery; D014148:Tranexamic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D000933:Antifibrinolytic Agents; D006490:Hemostatics; D017395:Plasminogen Activator Inhibitor 1; D015842:Serine Proteinase Inhibitors; D014148:Tranexamic Acid; D007611:Aprotinin; D015119:Aminocaproic Acid